Payment overview · 2025
General Payments
$1,560.72
89 reported records · 22 companies
Healthcare provider profile · identity verified
Roy Barco, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MUSCLE SHOALS, AL · NPI 1033436191
Verified facts
What the public records show
CMS Open Payments records show Roy Barco, M.D. received $1,560.72 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Nurtec Odt, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $279.22 | 17.9% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $182.01 | 11.7% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $174.37 | 11.2% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $112.05 | 7.2% | 5 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $91.85 | 5.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $81.01 | 5.2% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.98 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.81 | 3.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.30 | 3.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.12 | 3.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.25 | 3.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.06 | 3.3% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $49.58 | 3.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $48.95 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.88 | 2.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.32 | 2.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.54 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.56 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.37 | 1.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.65 | 1.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.26 | 1.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.58 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,560.72 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $202.74 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $154.51 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $112.05 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $111.08 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.04 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $100.04 | 9 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $91.85 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.51 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $62.74 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $59.98 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.81 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.81 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $57.30 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $49.58 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $48.95 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.15 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.67 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 160 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
160 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 828 | 166 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 571 | 85 |
| Pregabalin | Pregabalin | 550 | 106 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 535 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 131 |
| Clonazepam | Clonazepam | 429 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 141 |
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 146 |
| Omeprazole | Omeprazole | 371 | 121 |
| Lisinopril | Lisinopril | 365 | 119 |
| Tramadol Hcl | Tramadol Hcl | 364 | 84 |
| Montelukast Sodium | Montelukast Sodium | 341 | 97 |
| Metformin Hcl | Metformin Hcl | 281 | 109 |
| Zolpidem Tartrate | Zolpidem Tartrate | 240 | 35 |
| Furosemide | Furosemide | 239 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 64 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 223 | 66 |
| Trazodone Hcl | Trazodone Hcl | 220 | 67 |
| Potassium Chloride | Potassium Chloride | 216 | 61 |
| Losartan Potassium | Losartan Potassium | 213 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 67 |
| Meloxicam | Meloxicam | 192 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 65 |
| Celecoxib | Celecoxib | 182 | 60 |
| Sertraline Hcl | Sertraline Hcl | 169 | 53 |
| Alprazolam | Alprazolam | 165 | 30 |
| Methocarbamol | Methocarbamol | 163 | 63 |
| Mounjaro | Tirzepatide | 160 | 32 |
| Buspirone Hcl | Buspirone Hcl | 155 | 44 |
| Famotidine | Famotidine | 153 | 56 |
| Alendronate Sodium | Alendronate Sodium | 150 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 138 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 51 |
| Metformin Hcl Er | Metformin Hcl | 125 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 122 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 45 |
| Allopurinol | Allopurinol | 117 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 31 |
| Lorazepam | Lorazepam | 104 | 18 |
| Carvedilol | Carvedilol | 103 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 35 |
| Eliquis | Apixaban | 100 | 19 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 99 | 14 |
| Ezetimibe | Ezetimibe | 94 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 32 |
| Ondansetron Odt | Ondansetron | 88 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 33 |
| Trulicity | Dulaglutide | 84 | 26 |
| Promethazine Hcl | Promethazine Hcl | 82 | 17 |
| Atenolol | Atenolol | 81 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 22 |
| Diazepam | Diazepam | 77 | 14 |
| Modafinil | Modafinil | 77 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 72 | 16 |
| Spironolactone | Spironolactone | 71 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 23 |
| Farxiga | Dapagliflozin Propanediol | 67 | 21 |
| Methylprednisolone | Methylprednisolone | 67 | 64 |
| Topiramate | Topiramate | 65 | 21 |
| Bupropion Xl | Bupropion Hcl | 64 | 17 |
| Linzess | Linaclotide | 63 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 63 | suppressed |
| Mirtazapine | Mirtazapine | 62 | 15 |
| Temazepam | Temazepam | 59 | suppressed |
| Azithromycin | Azithromycin | 57 | 56 |
| Glimepiride | Glimepiride | 55 | 18 |
| Prednisone | Prednisone | 55 | 32 |
| Jardiance | Empagliflozin | 53 | 11 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 18 |
| Benazepril Hcl | Benazepril Hcl | 52 | 16 |
| Ibuprofen | Ibuprofen | 51 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 49 | suppressed |
| Glipizide | Glipizide | 47 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 47 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Simvastatin | Simvastatin | 46 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 19 |
| Sodium Chloride | Sodium Chloride 0.45 % | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 19 |
| Nystatin | Nystatin | 42 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 33 |
| Valacyclovir | Valacyclovir Hcl | 38 | 14 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | 15 |
| Propranolol Hcl | Propranolol Hcl | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 16 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Torsemide | Torsemide | 31 | 15 |
| Armodafinil | Armodafinil | 30 | suppressed |
| Baclofen | Baclofen | 30 | 12 |
| Buprenorphine Hcl | Buprenorphine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 14 |
| Ozempic | Semaglutide | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Anastrozole | Anastrozole | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Dayvigo | Lemborexant | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 11 |
| Bumetanide | Bumetanide | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Xyosted | Testosterone Enanthate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ztlido | Lidocaine | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Epclusa | Sofosbuvir/Velpatasvir | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,560.72 · 89 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, BRIXADI, CAPLYTA, CONTRAVE, Cologuard Collection Kit, EVENITY, FANAPT, FARXIGA, INSPIRE, JOURNAVX, Kerendia, Korlym, MAVYRET, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, RELISTOR, REPATHA, REXULTI, SUBLOCADE, TRULANCE, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error